Lisa A. Carey, MD, and Ingrid A. Mayer, MD, on Triple-Negative Breast Cancer: Treatment Challenges
2016 San Antonio Breast Cancer Symposium
Lisa A. Carey, MD, of the University of North Carolina, and Ingrid A. Mayer, MD, of the Vanderbilt-Ingram Cancer Center, discuss the current studies on neoadjuvant systemic treatment in the triple-negative disease setting.
Jame Abraham, MD, of the Cleveland Clinic, gives his perspective on study results of extended adjuvant endocrine therapy in postmenopausal women with estrogen receptor–positive breast cancer who have completed previous adjuvant endocrine treatment (Abstract S1-05).
Anne Hudson Blaes, MD, of the University of Minnesota, discusses the association between aromatase inhibitors, endothelial function, and early heart disease (Abstract S5-07).
Jennifer K. Litton, MD, of MD Anderson Cancer Center, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss a range of issues for young women with breast cancer, including epidemiologic and biologic differences in younger patients, fertility issues, and pregnancy-associated breast cancer (Poster Discussion 6).
Samuel Smith, PhD, of Queen Mary University of London, discusses study findings on menopausal symptoms as predictors of long‐term adherence in an International breast cancer intervention study (Abstract S5-03).
Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and breast cancer overall survival (Abstract S5-04).